These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31506496)

  • 1. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
    Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
    Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
    Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
    BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
    López-Knowles E; Wilkerson PM; Ribas R; Anderson H; Mackay A; Ghazoui Z; Rani A; Osin P; Nerurkar A; Renshaw L; Larionov A; Miller WR; Dixon JM; Reis-Filho JS; Dunbier AK; Martin LA; Dowsett M
    Breast Cancer Res; 2015 Mar; 17(1):35. PubMed ID: 25888249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
    Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
    Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
    Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
    Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
    Gao Q; López-Knowles E; Cheang MCU; Morden J; Ribas R; Sidhu K; Evans D; Martins V; Dodson A; Skene A; Holcombe C; Mallon E; Evans A; Bliss JM; Robertson J; Smith I; Martin LA; Dowsett M;
    Breast Cancer Res; 2019 Dec; 22(1):2. PubMed ID: 31892336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients.
    Liu H; Wang J; Zhang M; Xuan Q; Wang Z; Lian X; Zhang Q
    Breast Cancer Res Treat; 2017 Nov; 166(1):95-107. PubMed ID: 28730338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
    Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer.
    Brechbuhl HM; Xie M; Kopin EG; Han AL; Vinod-Paul K; Hagen J; Edgerton S; Owens P; Sams S; Elias A; Sartorius CA; Tan AC; Kabos P
    Mol Carcinog; 2022 Mar; 61(3):359-371. PubMed ID: 34856027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
    Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
    Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
    Chen Z; Wang Y; Warden C; Chen S
    J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells.
    Deng Y; Guo W; Xu N; Li F; Li J
    Mol Carcinog; 2020 May; 59(5):512-519. PubMed ID: 32124501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
    Chan HJ; Petrossian K; Chen S
    J Steroid Biochem Mol Biol; 2016 Jul; 161():73-83. PubMed ID: 26277097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
    Wang Y; Gong X; Zhang Y
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
    Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ER
    Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
    Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.